Market Data
News
Tools
Markets
Discover
Subscribe Login/Register
FTSE 100
7,607.28
(
1.56%
)
Dow Jones
33,762.76
(
2.12%
)
Gold vs US Dollar
1,948.195
(
0.0%
)
Brent Oil
76.235
(
0.0%
)
Bitcoin
27,144.65
(
0.25%
)
 

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Ergomed Plc (ERGO)

  7. Ergomed Plc (ERGO) Share Price

ERGO

Ergomed Plc

970.00
-30.00 (-3.0%)
Upgrade to Real-Time
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
Upgrade Icon
  -30.00 -3.0% 970.00 101,767 16:35:24
Bid Price Offer Price High Price Low Price Open Price
971.00 980.00 1,002.00 970.00 991.00
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:22 O 1,276 969.903 GBX
Related Shares
Astrazeneca (AZN), Gsk (GSK), Fusion Antibodies (FAB), Yourgene Health (YGEN)

Ergomed (ERGO) Latest News (1)

Ergomed News

Date Time Source Headline
02/6/202316:48UKREGErgomed plc TR1 Notification
26/5/202308:38UKREGErgomed plc Notice of AGM and Annual Report
19/4/202307:00UKREGErgomed plc Director's Dealing
17/4/202307:00UKREGErgomed plc Holding(s) in Company
13/4/202315:27UKREGErgomed plc Holdings in Company
03/4/202309:51UKREGErgomed plc Holding(s) in Company
03/4/202307:00UKREGErgomed plc Total Voting Rights
30/3/202315:37UKREGErgomed plc Holding(s) in Company
21/3/202310:16ALNCNewsErgomed sees profit rise on organic and operational growth in 2022
21/3/202307:00UKREGErgomed plc Ergomed Preliminary Results 2022
Smart Money!
ERGO is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BLACKROCK SMALLER COMPANIES TRUST PLC 2.00% 2022-12-31

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
17/5/202315:11Ergomed PLC1,025
14/1/202010:16Stephen Stamp, CFO of Ergomed (ERGO)2

Add a New Thread

Ergomed (ERGO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Ergomed (ERGO) Top Chat Posts

Top Posts
Posted at 29/1/2023 11:03 by maddox
Richard Barfield has been extremely impressive so very grateful for his contribution to the transformation of ERGO. He will be a difficult act to follow. However, the strategy is set and the execution going exceedingly well so his contribution will be sustained.

He has a c. 1m options on shares which is equivalent to about 2% of ERGO, so we'll have to see what he does with these. Hopefully he'll retain a sizeable holding in ERGO and an informal, if not formal, advisory role in future.

Apart from that I like to express my thanks as a shareholder and wish him a very long and very, very happy retirement. If you share my sentiments please give this post a thumbs-up.

Cheers Maddox
Read Full Thread
Follow
Reply
Posted at 26/1/2023 12:28 by ihatemms
Richard Barfield retiring is a big negative on the stock unfortunately. In short he transformed his previous company and then Ergomed - check the share price after he was appointed .The retirement expectation was on the wall when the deputy CFO was appointed. I sold half before the announcement and the other half yesterday.
Read Full Thread
Follow
Reply
Posted at 26/1/2023 10:56 by fegger
Positive trading update. https://uk.advfn.com/stock-market/london/ergomed-ERGO/share-news/Ergomed-plc-Ergomed-2022-Trading-Update/90051338?xref=newsalert

But no move in share price. Likely due to the still high PE ratio in an era where PEs have reduced a lot.
Read Full Thread
Follow
Reply
Posted at 17/2/2022 17:27 by km18
...from last year...

Company overview:
Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years.
Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/ERGO/46
Read Full Thread
Follow
Reply
Posted at 25/1/2022 09:20 by maddox
Hi Guys,

I appreciate we're all a bit share shocked but this was an excellent trading update:

>> Adjusted EBITDA ahead of mkt expectations (1)

>> Revenue growth 37.3% (44.3% at constant currency)

>> US very strong growth 59.5% (71% at constant currency)

>> Throwing off cash.

And the Outlook is positive - order book is up 24% and in value is twice 2021 revenue. So, conversion should ensure strong growth continues.

Regards Maddox

(1) I wish they would state a figure for 'market expectations' - it's public domain so why not?
Read Full Thread
Follow
Reply
Posted at 19/1/2022 10:02 by whittler100
ERGO is an Ex-holding that did exceptionally well for me. However, in this market, I do question the PE valuation ascribed to the businesses by the market. I think that ERGO is a fine business but will wait until the next trading update before I reconsider taking a fresh position. I expect the next trading update to be in eh last week of this month.
Read Full Thread
Follow
Reply
Posted at 24/9/2021 15:34 by piedro
Ergomed@ErgomedPLC
NEWS: We are delighted to share with both our customers and employees
the new Ergomed Clinical Research website. It provides easier access to
our solutions and services along with some integrated features and tools to
assist in planning clinical trials.

hTTps://ergomedcro.com
Read Full Thread
Follow
Reply
Posted at 08/8/2021 18:20 by sharesoc
In case you missed our webinar with Ergomed the recording and stockopedia report can be found here: hxxps://www.sharesoc.org/seminar/sharesoc-webinar-with-ergomed-plc-ergo-29-july-2021/

To access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc.org/membership/

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc.org/contact-us/
Read Full Thread
Follow
Reply
Posted at 31/7/2021 13:31 by etarip
See:

hxxps://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-ergo/ergomed-shares/news/if-you-like-eps-growth-then-check-out-ergomed-lonergo-before
Read Full Thread
Follow
Reply
Posted at 24/6/2019 20:04 by timbo003
I had assumed that the recent perkiness in the Ergo share price was due to them shifting away from the co-development model and just focusing on the pharmaceutical services parts of the business. Unfortunately I couldn't get to the AGM earlier this year, if I had gone, I had lots of questions about that. If they end up making the transition completely, I wonder if they are contemplating selling the future royalty streams from the current co-development portfolio? I suspect there would be plenty of potential buyers.
Read Full Thread
Follow
Reply
Ergomed share price data is direct from the London Stock Exchange
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230604 07:30:05